These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 11349808)
1. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Alvarnas JC; Linn YC; Hope EG; Negrin RS Biol Blood Marrow Transplant; 2001; 7(4):216-22. PubMed ID: 11349808 [TBL] [Abstract][Full Text] [Related]
2. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169 [TBL] [Abstract][Full Text] [Related]
3. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Linn YC; Hui KM Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644 [TBL] [Abstract][Full Text] [Related]
4. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Hongeng S; Petvises S; Worapongpaiboon S; Rerkamnuaychoke B; Pakakasama S; Jootar S Int J Hematol; 2003 Feb; 77(2):175-9. PubMed ID: 12627854 [TBL] [Abstract][Full Text] [Related]
5. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215 [TBL] [Abstract][Full Text] [Related]
6. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo. Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634 [TBL] [Abstract][Full Text] [Related]
7. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236 [TBL] [Abstract][Full Text] [Related]
8. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Linn YC; Lau LC; Hui KM Br J Haematol; 2002 Jan; 116(1):78-86. PubMed ID: 11841399 [TBL] [Abstract][Full Text] [Related]
9. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Fan ZP; Xu DP; Wang FS World J Gastroenterol; 2004 Apr; 10(8):1146-51. PubMed ID: 15069715 [TBL] [Abstract][Full Text] [Related]
10. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560 [TBL] [Abstract][Full Text] [Related]
11. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Mehta BA; Schmidt-Wolf IG; Weissman IL; Negrin RS Blood; 1995 Nov; 86(9):3493-9. PubMed ID: 7579455 [TBL] [Abstract][Full Text] [Related]
12. Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood. Condiotti R; Zakai YB; Barak V; Nagler A Exp Hematol; 2001 Jan; 29(1):104-13. PubMed ID: 11164111 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells. Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. Wang FS; Liu MX; Zhang B; Shi M; Lei ZY; Sun WB; Du QY; Chen JM World J Gastroenterol; 2002 Jun; 8(3):464-8. PubMed ID: 12046071 [TBL] [Abstract][Full Text] [Related]
15. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C Front Immunol; 2019; 10():2816. PubMed ID: 31849984 [TBL] [Abstract][Full Text] [Related]
16. Functional evaluation of ex vivo expanded cord blood lymphocytes: possible use for adoptive cellular immunotherapy. Azuma H; Yamada Y; Shibuya-Fujiwara N; Yamaguchi M; Murahashi H; Fujihara M; Sato N; Fukazawa K; Ikebuchi K; Ikeda H Exp Hematol; 2002 Apr; 30(4):346-51. PubMed ID: 11937270 [TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472 [TBL] [Abstract][Full Text] [Related]
19. Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15. Xiong Y; Mouginot M; Reppel L; Qian C; Stoltz JF; Bensoussan D; Decot V Immunol Res; 2017 Dec; 65(6):1130-1138. PubMed ID: 29019081 [TBL] [Abstract][Full Text] [Related]
20. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Linn YC; Lau SK; Liu BH; Ng LH; Yong HX; Hui KM Immunology; 2009 Mar; 126(3):423-35. PubMed ID: 18778291 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]